• The broad market context is pushing money toward high-beta bets
• MGRX is a prime example of the genre, with shares launching
• The move is tied to the company’s dramatic expansion into high-growth verticals
• MGRX has a tiny market cap but could be a leader in the ascending Men’s Health marketplace

The market has started to catch fire. And, like most times when we see this, that fire is burning up a store of too much bearishness that had been weighing on prices a few weeks ago. When people get too bearish, it signals something about positioning—how the market is “held”. In late October, we saw way too many puts being bought, way too much cash in the portfolios of fund managers, and way too much net short interest among hedge fund managers.

In fact, in all three cases, we were seeing multi-year extremes driven by uncertainties surrounding monetary policy, geopolitics (with war breaking out in the Middle East), earnings forecasts, and domestic politics (with the US House rendered Speaker-less for the first time ever).

At the same time, we were on the precipice of the stock market’s seasonally strongest period of the year—in November and December. With everyone leaning short or on the sidelines and the seasonal edge setting in, it’s not overly surprising to see a dramatic rally now underway.

That rally has set off a number of historic “Buy” signals for investors across the market, including the legendary Zweig Breadth Thrust, which has happened 17 times since 1945 and has never been wrong in that time span.

With such a dramatic swing from bearish to bullish energy, investors are looking for how to best capitalize on the party. Historically, such instances favor high-beta stocks—more speculative plays with the potential to move big from low levels.

One such opportunity in our sights right now is Mangoceuticals, Inc. (NASDAQ: MGRX), an up-and-coming Nasdaq small cap launching disruptive products and services focused on the rapidly growing $31 billion men’s health and wellness marketplace.

Context

MGRX—Mango (think: “Man, Go!”)—has been defined by its men’s health products over the past year.

The company offers a special formulation featuring leading active ingredients in combination with other FDA approved ingredients to maximize efficacy. And it’s all packaged in a rapidly dissolved orally absorbed tablet capable of producing results in 15 minutes, with effects lasting up to 36 hours.

The other interesting edge the company has put in place, as noted above, is its unique telemedicine platform. Mango is a prescription medication that must be approved by a physician. But the company has set up a telehealth infrastructure to aid in that process: After an individual has completed an online telehealth visit, MGRX’s network of medical providers will review and approve a prescription if medically appropriate, and then send the product immediately to the customer.

On the marketing side, the company has built a platform leveraging social media and the podcast universe to drive rapidly growing awareness. This effort has been powered by partnerships with the GaS Network, Barstool Sports, Only Stans, Adam22, No Jumper. The company is finding its place in the mix with a target on non-traditional ad strategies where the key is its focus on outlets with a strong and proven appeal to a younger male demographic.

Expanding Verticals

All of this has been prologue to the company’s much-anticipated expansion into other verticals, including hair loss, weight loss, performance, and various hormone therapies.

The first expansion step is clearly underway in the form of the company’s new laboratory partnership with TRYBE Labs. As noted in the company’s release earlier this week, MGRX announced that it has selected TRYBE Labs to provide its customers with a minimally invasive FDA approved at-home blood collection device and testing services as the Company seeks to further expand its product lines requiring blood tests and results reviewed by physicians.

According to the release, using innovative, FDA approved at-home blood collection technology, TRYBE Labs is a CLIA certified and Joint Commission accredited laboratory that provides a direct-to-consumer product which includes an easy-to-use collection kit, full range of testing, and physician-read results for male health and performance evaluation – including hormone, thyroid and vitamin levels.

“As we have been continuously working to bring additional pharmaceutical based products and solutions to market, the requirement for our physicians to review up-to-date blood work and results has become paramount,” said Jacob Cohen, MangoRx’s co-founder and CEO. “TRYBE Labs offers a unique, innovative, convenient, and minimally invasive approach for blood collection and testing along with fast result turnaround times (in as little as 72 hours) for patients across the United States. What makes our partnership that much greater is that TRYBE Labs and MangoRx are completely aligned with our respective approaches in being disruptive in our industries and we are thrilled to work with them and their team on this endeavor.”

The release also notes that TRYBE Labs will also be joining the Company as one of their affiliate marketing partners to further create awareness and drive sales of MangoRx’s men’s health and wellness related products through its own direct-to-consumer marketing efforts.

“TRYBE Labs was built by men, for men,” said Lewis Scalione, Founding Partner, TRYBE Labs. “We know many men are hesitant to seek medical care and that they may struggle with the perceived stigma that comes with low energy or suboptimal performance – at the gym or in the intimate moments of their lives. By putting the power of information and cutting-edge technology directly into their hands, we are making healthcare more accessible to all who need it.”

The post The Rise of MGRX .. Shares Launch as Long-Awaited Expansion Takes Flight appeared first on Wall Street PR.